Our results suggest that HDAC6 inhibitors may restore cellular adaptations induced by chronic disease states but may not otherwise affect healthy physiological function; and such compounds could contribute to the migraine therapeutic armamentarium. Here, HDAC6 is linked to migraine disorder.